Jun 2026 (Q2 FY26) — Aug 6, 2026
CytoSorbents Q2 FY26 — Strong Progress Towards Cash Flow Breakeven and DrugSorb-ATR Regulatory Clarity
Read the full callCytoSorbents (CTSO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
CytoSorbents earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 9.6 | +0.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -27.4 | +10.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -4.4 | −326.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$3.06 −0.97% · −$0.03
Performance +232.6% 1Y
1Y: $0.92 on 14 Oct 2025 → $3.06. High $7.68 (2 Sept 2026), low $0.31 (20 Aug 2026).
- Previous close
- $3.09
- 52-week range
- $0.31 – $7.68
- One year
- +232.61%
Overview
- Symbol
- CTSO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
CytoSorbents earnings calls (CTSO)
Financials
What the filings say
Net profit, year on year: −327% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 7 | 9 | 10 | 9 | 9 | 9 | 10 |
| Operating profit | -5 | -4 | -4 | -4 | -3 | -4 | -3 | -3 |
| Operating margin | −56.1% | −62.0% | −44.5% | −37.6% | −30.2% | −47.5% | −34.3% | −27.4% |
| Other income | 2 | -6 | 2 | 6 | -1 | -1 | -2 | -2 |
| Profit before tax | -3 | -10 | -1 | — | -4 | -5 | — | — |
| Tax rate | 0.0% | 17.7% | 0.0% | — | 11.2% | 0.0% | — | — |
| Net profit | -3 | -8 | -1 | 2 | -3 | -5 | -5 | -4 |
| EPS ($ per share) | -0.05 | — | -0.02 | 0.03 | -0.05 | — | -0.08 | -0.07 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -170 | -189 | -197 | -221 | -254 | -283 | -304 | -312 |
| Total liabilities | 17 | 24 | 11 | 27 | 28 | 29 | 36 | 38 |
| Fixed assets | 2 | 2 | 2 | 5 | 11 | 10 | 9 | 8 |
| Total assets | 34 | 27 | 90 | 90 | 63 | 53 | 47 | 44 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -11 | -17 | -6 | -14 | -28 | -22 | -14 | -12 |
| Cash from investing | -2 | -2 | -2 | -4 | -6 | -1 | -1 | -0 |
| Cash from financing | 17 | 8 | 66 | 1 | 5 | 14 | 9 | 9 |
| Net cash flow | 5 | -10 | 59 | -18 | -30 | -8 | -6 | -2 |
| Capital expenditure | -1 | -1 | -1 | -4 | -6 | -1 | -0 | -0 |
| Free cash flow | -12 | -17 | -6 | -18 | -34 | -22 | -15 | -13 |
Insider filings
11 filings between Nov 18, 2025 and Sep 15, 2026.
Open market
decisions to buy or sellPurchases
$269.3K
10 purchases by 4 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 1
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Chan Phillip P. | $197.5K | — | Sep 15, 2026 |
| MARIANI PETER J | $44.0K | — | Jun 15, 2026 |
| Sobel Alan D. | $15.3K | — | Sep 15, 2026 |
| Capponi Vincent | $12.5K | — | Sep 14, 2026 |
Latest filings (29)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Sobel Alan D. Director | Purchase | 500 | $3.0K |
| Sep 15, 2026 | Sobel Alan D. Director | Purchase | 100 | $601 |
| Sep 15, 2026 | Chan Phillip P. Chief Executive Officer | Purchase | 3,774 | $22.6K |
| Sep 15, 2026 | Sobel Alan D. Director | Purchase | 1,900 | $11.6K |
| Sep 14, 2026 | Capponi Vincent President and COO | Purchase | 273 | $1.6K |
| Sep 14, 2026 | Capponi Vincent President and COO | Purchase | 1,800 | $10.9K |
| Sep 4, 2026 | Chan Phillip P. Chief Executive Officer | Purchase | 200,000 | $70.0K |
| Jun 15, 2026 | MARIANI PETER J Chief Financial Officer | Purchase | 100,000 | $44.0K |
| Jun 15, 2026 | Chan Phillip P. Chief Executive Officer | Purchase | 10,333 | $4.4K |
| Jun 12, 2026 | Chan Phillip P. Chief Executive Officer | Purchase | 251,136 | $100.5K |
| Nov 18, 2025 | Chan Phillip P. Chief Executive Officer | Award | 100,000 | $64.0K |
| Aug 8, 2025 | Chan Phillip P. Chief Executive Officer | Award | 105,600 | $0 |
| Aug 8, 2025 | Deliargyris Efthymios Chief Medical Officer | Award | 70,000 | $0 |
| Aug 8, 2025 | Capponi Vincent President and COO | Award | 89,100 | $0 |
| Aug 8, 2025 | MARIANI PETER J Chief Financial Officer | Award | 71,500 | $0 |
| Feb 24, 2025 | BATOR MICHAEL G. Director | Code O | 10,000 | $11.3K |
| Feb 24, 2025 | Sobel Alan D. Director | Code O | 21,950 | $24.8K |
| Feb 24, 2025 | Chan Phillip P. Chief Executive Officer | Code O | 34,168 | $38.6K |
| Feb 24, 2025 | MARIANI PETER J Chief Financial Officer | Code O | 32,625 | $36.9K |
| Feb 24, 2025 | Capponi Vincent President and COO | Code O | 12,000 | $13.6K |
| Jan 17, 2025 | Chan Phillip P. Chief Executive Officer | Option exercised | 90,832 | $90.8K |
| Jan 17, 2025 | MARIANI PETER J Chief Financial Officer | Option exercised | 32,625 | $32.6K |
| Jan 17, 2025 | Sobel Alan D. Director | Option exercised | 21,950 | $21.9K |
| Jan 17, 2025 | Capponi Vincent President and COO | Option exercised | 31,760 | $31.8K |
| Jan 17, 2025 | BATOR MICHAEL G. Director | Option exercised | 15,879 | $15.9K |
| Jan 17, 2025 | Deliargyris Efthymios Chief Medical Officer | Option exercised | 16,233 | $16.2K |
| Dec 13, 2024 | MARIANI PETER J Chief Financial Officer | Purchase | 20,000 | $19.3K |
| Dec 12, 2024 | MARIANI PETER J Chief Financial Officer | Purchase | 20,000 | $17.9K |
| Dec 11, 2024 | MARIANI PETER J Chief Financial Officer | Purchase | 11,363 | $10.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Cytosorbents Corp
Free account. Everything above stays public.
Write why you follow Cytosorbents Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading